ACZ885
CACZ885D2304
Phase 3 small_molecule completed
Quick answer
ACZ885 for Muckle Wells Syndrome is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Muckle Wells Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed